Antimicrobial development in the era of emerging resistance.

Abstract

Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). Moreover, all of them would be useful for skin and soft tissue infections.

• Authors: Antonio Sorlozano, Cristina Carrasco, Jose Cabeza, Enrique Villegas, Jose Gutierrez
• Journal: Mini reviews in medicinal chemistry (Mini Rev Med Chem) Vol. 9 Issue 8 Pg. 938-55 (Jul 2009) ISSN: 1389-5575 [Print] Netherlands
• PMID: 19601889 (Publication Type: Journal Article)

Chemical References

• Aminoglycosides
• Anti-Bacterial Agents
• Cephalosporins
• Glycopeptides
• Lipoglycopeptides
• Pyrimidines
• beta-Lactams
• iclaprim
• ceftobiprole
• Teicoplanin
• dalbavancin
• fropenem
• oritavancin
• telavancin

Topics

• Aminoglycosides (adverse effects, chemistry, pharmacology, therapeutic use)
• Animals
• Anti-Bacterial Agents (adverse effects, chemistry, pharmacology, therapeutic use)
• Bacteria (drug effects)
• Cephalosporins (adverse effects, chemistry, pharmacology, therapeutic use)
• Drug Approval
• Drug Resistance, Bacterial
• Glycopeptides (adverse effects, chemistry, pharmacology, therapeutic use)
• Humans
• Lipoglycopeptides
• Pyrimidines (adverse effects, chemistry, pharmacology, therapeutic use)
• Skin Diseases, Bacterial (drug therapy)
• Skin Diseases, Viral (drug therapy)
• Teicoplanin (adverse effects, analogs & derivatives, chemistry, pharmacology, therapeutic use)
• United States
• United States Food and Drug Administration
• beta-Lactams (adverse effects, chemistry, pharmacology, therapeutic use)